These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28341670)

  • 1. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
    Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
    J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
    Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
    Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GUCY2C-targeted cancer immunotherapy: past, present and future.
    Snook AE; Magee MS; Waldman SA
    Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.
    Belyakov IM; Ahlers JD; Nabel GJ; Moss B; Berzofsky JA
    Virology; 2008 Nov; 381(1):106-15. PubMed ID: 18793787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
    Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
    Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
    J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
    Snook AE; Baybutt TR; Hyslop T; Waldman SA
    Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
    Snook AE; Stafford BJ; Li P; Tan G; Huang L; Birbe R; Schulz S; Schnell MJ; Thakur M; Rothstein JL; Eisenlohr LC; Waldman SA
    J Natl Cancer Inst; 2008 Jul; 100(13):950-61. PubMed ID: 18577748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
    Snook AE; Li P; Stafford BJ; Faul EJ; Huang L; Birbe RC; Bombonati A; Schulz S; Schnell MJ; Eisenlohr LC; Waldman SA
    Cancer Res; 2009 Apr; 69(8):3537-44. PubMed ID: 19351847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
    Flickinger JC; Singh J; Carlson R; Leong E; Baybutt TR; Barton J; Caparosa E; Pattison A; Rappaport JA; Roh J; Zhan T; Bashir B; Waldman SA; Snook AE
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
    Snook AE; Magee MS; Schulz S; Waldman SA
    Eur J Immunol; 2014 Jul; 44(7):1956-66. PubMed ID: 24771148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells.
    Qi C; Liu D; Liu C; Wei X; Ma M; Lu X; Tao M; Zhang C; Wang X; He T; Li J; Dai F; Ding Y; Shen L
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39366753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
    Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
    Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity.
    Tenbusch M; Kuate S; Tippler B; Gerlach N; Schimmer S; Dittmer U; Uberla K
    BMC Immunol; 2008 Apr; 9():13. PubMed ID: 18405363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.
    Ranasinghe C; Eyers F; Stambas J; Boyle DB; Ramshaw IA; Ramsay AJ
    Vaccine; 2011 Apr; 29(16):3008-20. PubMed ID: 21352941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy.
    Flickinger JC; Staudt RE; Singh J; Carlson RD; Barton JR; Baybutt TR; Rappaport JA; Zalewski A; Pattison A; Waldman SA; Snook AE
    NPJ Vaccines; 2022 Jun; 7(1):61. PubMed ID: 35739202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GUCY2C: at the intersection of obesity and cancer.
    Kim GW; Lin JE; Waldman SA
    Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.